Oxytocin has two almost separate literatures: a large obstetric one using intravenous infusion, and a large social-neuroscience one using intranasal administration. The intranasal behavioural literature converged on a single figure, and it is also the literature with the most serious replication problems.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
Class
Nonapeptide hormone
Reported half-life
Approximately 3–5 minutes intravenously
Routes used in the literature
Intranasal in behavioural research; intravenous in obstetric use
Also written as
Oxytocin acetate
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Intranasal social-cognition research
Reported quantity
24 IU (approximately 40 µg)
Frequency
Single administration before the task
Study duration
Testing window of 30–90 minutes after administration
24 IU became the field-standard figure largely by convention rather than by dose-finding.
Repeated intranasal arms
Reported quantity
24–48 IU per day
Frequency
Once or twice daily
Study duration
2–8 weeks
Longer arms report attenuation of the acute effects.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Oxytocin · 10 mg Vial
Oxytocin is dosed at 100 mcg–500 mcg daily in educational protocols, administered subcutaneously or intranasally. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
Reconstitute
Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range
100–500 mcg once daily (gradual titration).
Easy measuring
At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
Storage
Lyophilized: freeze at −20 °C (−4 °F) or refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 28–30 days.
The same arithmetic for every vial size Oxytocin is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
Oxytocin · 3 ml bacteriostatic water
Vial size
Concentration
Per 1 unit
100 mcg =
500 mcg =
2 mg
0.67 mg/ml
7 mcg
15 units
75 units
5 mg
1.67 mg/ml
17 mcg
6.0 units
30 units
Unit columns use the range reported for this compound (100 mcg–500 mcg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
Research powder is commonly 2 mg or 10 mg. 1 IU is approximately 1.67 µg, so 10 mg is roughly 6,000 IU — a mass-labelled vial and an IU-labelled one are easy to confuse by orders of magnitude.
The intranasal literature has well-documented replication failures; read meta-analyses, not single studies.
How much intranasal oxytocin reaches the central nervous system is genuinely contested.
IU-to-microgram conversion errors are the most common and most consequential mistake with this peptide.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
[1]
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Sikich L, Kolevzon A, King BH, et al. · N Engl J Med · 2021 · DOI 10.1056/NEJMoa2103583
Children and adolescents with ASD received intranasal oxytocin, titrated up to a maximum of 48 IU/day, over a 24-week placebo-controlled trial.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Share
Independent publication — we sell nothing. Supplier disclosure
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.